This inventor holds 1 USPTO granted patent. Top assignees: Oregon Health & Science University, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2019
Title: Namal Malimbada Liyanage: Innovator in HIV Research
Introduction
Namal Malimbada Liyanage is a notable inventor based in Rockville, MD (US). He has made significant contributions to the field of HIV research, particularly in developing methods to improve vaccine efficacy. His innovative work focuses on the Ras pathways as markers of protection against HIV.
Latest Patents
Liyanage holds a patent titled "Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy." This patent discloses compositions that include a therapeutically effective amount of an HIV immunogen combined with an agent that stimulates the Ras pathway, excluding aluminum salts. The methods outlined in the patent aim to induce an immune response to HIV and to inhibit or treat HIV infection in subjects. Additionally, the patent describes methods for determining the potential of an immunogenic composition to induce a protective response against HIV.
Career Highlights
Throughout his career, Liyanage has worked with prominent organizations, including the United States Department of Health and Human Services and Oregon Health & Science University. His work has been instrumental in advancing the understanding of HIV and developing potential therapeutic strategies.
Collaborations
Liyanage has collaborated with notable colleagues, including Mark Cameron and Monica Vaccari, who have contributed to his research endeavors.
Conclusion
Namal Malimbada Liyanage's innovative work in HIV research and his patent contributions highlight his commitment to improving vaccine efficacy and understanding the immune response to HIV. His efforts continue to pave the way for advancements in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile